This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
3 Mar 2014

New Liquid Chromatography Column Separates Challenging Glycans and Glycan Isomers

The growing legion of scientists investigating glycans as disease markers and antibody-based biopharmaceuticals (nearly 800 publications in 5 years) now have an effective new tool for the challenging separations of glycans and glycan isomers. Thermo Fisher Scientific will showcase the GlycanPac AXR-1 column at booth #2441 during Pittcon 2014, being held at McCormick Place in Chicago from 2–6 March.

­

“Until now, glycan isomers could not be separated by conventional HPLC,” said Ilze Birznieks, product marketing manager, biocolumns, for Thermo Fisher. “This new column helps users achieve greater resolution of glycans using HPLC, providing easier profile characterization. This is useful for characterizing glycans from monoclonal antibodies being developed for therapeutics.”

 

The GlycanPac AXR-1 columns are designed for excellent resolution of labeled and unlabeled glycans, and are compatible with fluorescence and mass spectrometry detection methods. Mass spectrometry has emerged as a powerful tool for determining the structures of glycans, and this new column is designed to enable researchers to harness the power of high-resolution accurate-mass (HRAM) mass spectrometry at high-throughput rates. This column is designed to separate both labeled and native glycans based on the availability of samples. Native glycan separation allows researchers to eliminate the fluorescent labeling step and increase throughput without eroding performance.

 

For a closer look at the GlycanPac AXR-1 column, visit Thermo Fisher at Pittcon booth #2441, or for more information, click here. 
 

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.